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Current antimitotics work by perturbing spindle assembly, which activates the spindle assembly checkpoint,
causes mitotic arrest, and triggers apoptosis. Cancer cells can resist such killing by premature exit, before
cells initiate apoptosis, due to a weak checkpoint or rapid slippage. We reasoned blockingmitotic exit down-
stream of the checkpoint might circumvent this resistance. Using single-cell approaches, we showed that
blocking mitotic exit by Cdc20 knockdown slowed cyclin B1 proteolysis, thus allowed more time for death
initiation. Killing by Cdc20 knockdown did not require checkpoint activity and can occur by intrinsic
apoptosis or an alternative death pathway when Bcl2 was overexpressed. We conclude targeting Cdc20,
or otherwise blocking mitotic exit, may be a better cancer therapeutic strategy than perturbing spindle
assembly.INTRODUCTION
Antimitotic drugs that target microtubule dynamics, including
taxanes, vinca alkaloids, and epothilones, are active against a
broad range of cancers, but they also cause neurotoxicity,
presumably due to perturbation of microtubules in neurons
(Jordan and Wilson, 2004). In an effort to develop antimitotic
drugs lacking this toxicity, small-molecule inhibitors of a number
of proteins specific to the mitotic spindle were developed,
including the motor protein kinesin-5 (KSP, Eg5, Kif11), Aurora
kinases, and Polo-like kinases (Jackson et al., 2007). In clinical
trials to date, these spindle-specific antimitotic drugs lack neuro-
toxicity as hoped, but their efficacy against solid tumors seems
to be no better than taxanes and vincas, and perhaps not as
good. Can we find an antimitotic strategy that not only lacks
neurotoxicity, but is also more effective than current strategies
at causing regression of solid tumors? We set out to address
this question using RNAi knockdown as a surrogate for potential
drugs, and comparing efficacy for killing cancer cell lines with
representative drugs that interfere with spindle assembly.The net effect of antimitotic drugs is to perturb mitotic spindle
assembly, which activates the spindle assembly checkpoint
(SAC). After many hours of SAC-induced mitotic arrest, cancer
cells either die inside mitosis, or exit mitosis by slippage into a
tetraploid G1 state, from which they either die, arrest in G1, or
initiate a new round of the cell cycle (Rieder and Maiato, 2004;
Gascoigne and Taylor, 2008; Orth et al., 2008). Slippage is
thought to occur by gradual proteolysis of cyclin B1, which
continues slowly even when the SAC is active (Brito and Rieder,
2006). Cell death occurs mainly via activation of the intrinsic
apoptosis (Wang et al., 1999; Park et al., 2004; Tao et al., 2005;
Bergstralh and Ting, 2006), a pathway involving mitochondrial
outer membrane permeabilization (MOMP) (Letai, 2008). Failure
to initiate apoptosis during or after mitotic arrest appears to be
a major factor limiting efficacy of antimitotic drugs because
mitotic arrest without subsequent apoptosis is commonly
observed following taxane treatment in various cancer cell lines
(Shi et al., 2008), mouse cancers (Milross et al., 1996), and,
though data are very limited, human breast cancers, where it
correlates with poor tumor responses (Symmans et al., 2000).SIGNIFICANCE
Drugs targeting spindle proteins, including kinesin-5, Aurora kinases, and Polo-like kinases, were recently developed in the
hope of providing less neurotoxic antimitotic drugs. In clinical trials to date, their efficacy seems no better than taxanes and
vincas.We provide evidence that an alternative antimitotic strategy, blockingmitotic exit, might bemore effective.We found
Cdc20 knockdown provides a checkpoint-independent mitotic arrest that kills cancer cells more effectively than spindle-
perturbing drugs. We suggest mitotic exit is a promising therapeutic target, and propose a cell-based screening strategy
for compounds with this mechanism. These findings are significant from a drug development perspective, and also as
a mechanistic step toward understanding how mitotic arrest triggers death, and how some cancer cells resist this trigger.Cancer Cell 16, 347–358, October 6, 2009 ª2009 Elsevier Inc. 347
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Mitotic Exit as an Antimitotic TargetHere, we focus on drug resistance caused by lack of apoptosis
downstream of spindle damage; clinical resistance might also
arise from mutations that prevent drugs from causing spindle
damage, e.g., due to target protein mutations or drug efflux
pump expression (Pusztai, 2007), from failure of cancer cells to
enter mitosis during drug exposure (Baguley et al., 1995), or
other causes.
Previous studies provide twomechanistic clues to how cancer
cells choose a nonapoptotic outcome following spindle damage
and mitotic arrest. First, they may fail to execute apoptosis effi-
ciently due to downregulation of apoptosis pathways. Protection
against MOMP at the level of Bcl2 protein family reduces sensi-
tivity to apoptosis promoted by paclitaxel and vinca alkaloids
(Tan et al., 2005; Deng et al., 2007; Kutuk and Letai, 2008).
Second, they may slip out of mitotic arrest before they die; in
other words, slippage and apoptosis can be viewed as two
competing pathways (Gascoigne and Taylor, 2008). Consistent
with slippage protecting cells from death, premature exit from
mitotic arrest due to a weakened or ablated SAC is known to
decrease sensitivity to spindle-perturbing drugs (Taylor and
McKeon, 1997; Shin et al., 2003; Tao et al., 2005; Swanton
et al., 2007; Gascoigne and Taylor, 2008; Bekier et al., 2009).
Based on these clues, we reasoned that blocking mitotic exit
downstream of the SAC may be a better strategy for killing
apoptosis-resistant, slippage-prone, or SAC-defective cancer
cells than any of the currently available antimitotic drugs, all of
which target spindle assembly.
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Figure 1. Cdc20 as a Potential Antimitotic
Drug Candidate
(A) Simplified pathway from spindle damage to
mitotic arrest.
(B) siRNA knockdown of Cdc20 in HeLa cells as
analyzed by immunoblotting for Cdc20 and
tubulin.
(C) Rescue of Cdc20 knockdown by expression of
an RNAi-resistant transgene to confirm the speci-
ficity of siRNA. HeLa cells infected with retrovirus
expressing control vector () or mouse Cdc20
cDNA with two extra silent mutations (mCdc20)
were transfected with control Lamin A/C () or
Cdc20 siRNA. Cell lysates were immunoblotted
for Cdc20 or tubulin.
(D) Phase-contrast time-lapse analysis of progres-
sion throughmitosis and death in HeLa cells under
conditions indicated at left. Numbers show
elapsed time (hour:minute) relative to mitotic
entry. Time of death (to the nearest frame) is indi-
cated as D, and mitotic exit is indicated as E. The
scale bar represents 5 mm.
(E) siRNA knockdown of Cdc20 inMDA-MB-435S,
MCF7, A549, and HeLa Bcl2-overexpressing cells
as analyzed by immunoblotting for Cdc20 and
tubulin.
RESULTS
Cdc20 Knockdown Causes Mitotic
Arrest and Cell Death
As surrogate for a potential drug that
directly blocks mitotic exit, we knocked
downCdc20 using siRNAs. Cdc20 activates the APC/C to trigger
cyclin B1 degradation during normal mitosis, and it is seques-
tered by SAC proteins when the spindle is damaged
(Figure 1A) (Musacchio and Hardwick, 2002; Musacchio and
Salmon, 2007). Cdc20 must be depleted to less than 5% of its
normal levels to arrest cells in mitosis (Wolthuis et al., 2008).
We tested several siRNA duplexes and hairpin constructs in
HeLa cells, and selected two duplexes on the basis of promoting
the most robust mitotic arrest, and most efficient knockdown by
immunoblotting (Figure 1B). All data shown are for duplex 1, but
similar results were obtained using duplex 2. HeLa cells depleted
of Cdc20 arrested in mitosis for an average of 18.8 ± 7.3 hr
(n = 98) before undergoing death in mitosis (Figure 1D, top
panel). Specificity is amajor concern for siRNA duplexes; to eval-
uate this, we performed a RNAi-resistant transgene rescue
experiment for duplex 1, using mouse Cdc20 cDNA with two
extra silent mutations (mCdc20) as the rescue construct
(Figure 1C). In HeLa cells infected with control vector, and trans-
fected with duplex 1, more than 98% underwent prolonged
arrest followed by death in mitosis. In cells infected with retro-
virus expressing mCdc20, and then transfected with duplex 1,
83% went through mitosis with little or no delay (1.5 ± 0.9 hr,
n = 85), divided, did not die, and continued to the next cell cycle
(Figure 1D, bottom panel). The remaining 17% that still showed
prolonged arrest may not have been infected with the rescue
construct. We conclude that the robust arrest and cell death
phenotype caused by duplex 1 is specific to knockdown of348 Cancer Cell 16, 347–358, October 6, 2009 ª2009 Elsevier Inc.
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Figure 2. Knockdown of Cdc20 Efficiently Kills Slippage-Prone and Apoptosis-Resistant Cancer Cells
Cumulative survival curves for indicated treatments in various cancer cell lines: HeLa (A and F), MDA-MB-435S (B and G), MCF7 (C and H), A549 (D and I), and
HeLa cells stably expressing Bcl2 (E and J). Individual cells were monitored by phase-contrast time-lapse microscopy, and time from mitotic entry to death was
measured and plotted as survival curves as a function of time sincemitotic entry. For Cdc20 siRNA transfection alone, only cells that entered and underwent > 6 hr
mitosis (varying from 30%–100%) are considered to be Cdc20 knocked down and included in our analysis. For all other treatments, all cells that entered mitosis
are analyzed. When cell division occurred, daughter cells were counted as one. Numbers in parentheses indicate number of cells scored.Cdc20. Duplex 1 also efficiently knocked down Cdc20 in four
other cell lines we investigated below (Figure 1E).
Cdc20 Knockdown Efficiently Kills Slippage-Prone
and Apoptosis-Resistant Cancer Cells
We next systematically compared the ability to promote death
during mitotic arrest between Cdc20 knockdown and treatment
with a mitosis-specific kinesin-5 inhibitor, EMD534085 (Orth
et al., 2008). We made this comparison in five solid-tumor-
derived cell lines: four were selected from a larger panel tested
previously so as to span the full range of death sensitivity when
treated with antimitotic drugs (Shi et al., 2008); Bcl2-overex-
pressing HeLa cells were added as a fifth line with a known
mechanism of apoptosis resistance. Because individual cells
vary greatly in their kinetics of mitotic arrest and death during
mitosis (Gascoigne and Taylor, 2008; Orth et al., 2008), we quan-
tified single-cell behavior using time-lapse microscopy. Figures
2A–2E show death kinetics in individual cells by time-lapse
phase-contrast imaging, where death was scored by vigorous
blebbing followed by cessation of all movement. Time of death
was normalized to time of mitotic entry, which was scored by
cell rounding. Because both kinesin-5 and Cdc20 are thought
to function only in mitosis, and death in both kinesin-5 inhibitor
and Cdc20 knockdown only occurred during or after mitotic
arrest, normalizing so that T = 0 was the time of mitotic entry
conceptually synchronizes all cells at the start of the prodeathstimulus. These data compare four treatments: lamin A/C siRNA
alone (to control for the toxicity of siRNA transfection), kinesin-5
inhibitor plus laminA/CsiRNA,Cdc20siRNA, andkinesin-5 inhib-
itor plus Cdc20 siRNA. A saturating concentration of kinesin-5
inhibitor was used, so all drug-treated cells that entered mitosis
arrested, and none succeeded in executing cytokinesis. For kine-
sin-5 inhibitor treatment, we observed some death in mitosis,
some slippage, and some death after slippage in all lines. These
data are reported separately in Table 1. For simplicity, Figures
2A–2E report kinetics of all death, whether it occurred before or
after slippage, as cumulative survival curves. For Cdc20 knock-
down, we observed no slippage. HeLawas themost death sensi-
tive in our previous profiling experiment (Shi et al., 2008). In this
line, more than 90%of cells died duringmitotic arrest for all treat-
ments except control siRNA alone, and death kinetics were
similar in each case (Figure 2A). In moderately resistant MDA-
MB-435S, 15% cells slipped out of kinesin-5 inhibitor-induced
mitotic arrest and survived, and in highly resistant MCF7 and
A549, 80% slipped and survived (blue lines in Figures 2B, 2C,
and 2D; Table 1). In each of these lines, knockdown of Cdc20
prevented slippage, regardless of whether kinesin-5 inhibitor
was present. All Cdc20 knocked-down cells remained arrested
in mitosis for the whole time course, and all eventually died (red
and green lines in Figures 2B, 2C, and 2D).
The molecular origin of death resistance in MCF7 and A549 is
incompletely understood. To compare Cdc20 knockdown withCancer Cell 16, 347–358, October 6, 2009 ª2009 Elsevier Inc. 349
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Mitotic Exit as an Antimitotic TargetTable 1. Duration of Mitosis and Percentage of Cell Death in Response to Kinesin-5 Inhibitor or Paclitaxel Incubated with Lamin A/C
siRNA
Cell Line
Kinesin-5 Inhibitor Paclitaxel
Duration of
Mitosis ± SD (hr)
Death
(%)a
D in
M (%)b
D after
E (%)c
Duration of
Mitosis ± SD (hr)
Death
(%)a
D in
M (%)b
D after
E (%)c
HeLa 19.7 ± 7.7 (n = 62) 98.4 90.3 8.1 21.3 ± 6.8 (n = 142) 100.0 100.0 0.0
MDA-MB-435S 23.6 ± 6.3 (n = 66) 84.9 77.3 7.6 24.9 ± 7.9 (n = 63) 88.9 71.4 17.7
MCF7 19.2 ± 6.6 (n = 63) 21.0 8.1 12.9 15.7 ± 7.3 (n = 82) 13.4 2.4 11.0
A549 17.9 ± 4.0 (n = 76) 20.8 6.5 14.3 16.3 ± 4.4 (n = 93) 79.6 5.4 74.2
HeLa Bcl2 OEd 19.7 ± 8.8 (n = 72) 27.8 15.3 12.5 20.1 ± 7.1 (n = 92) 52.2 6.5 45.7
a Percentage of total cell death.
b Percentage of death in mitosis.
c Percentage of death after mitotic exit.
d HeLa cells overexpressing Bcl2.kinesin-5 inhibitor in cells where we know the origin of death
resistance, we used a HeLa line that stably overexpresses
Bcl2. Bcl2 antagonizes MOMP, and overexpression of Bcl2
and related family members has been widely implicated in
apoptosis resistance in cancer (Letai, 2008). More than 70% of
HeLa cells overexpressing Bcl2 slipped out of mitotic arrest
induced by kinesin-5 inhibitor, and survived (blue line in Fig-
ure 2E; Table 1), like the naturally death-resistant cancer lines.
Cdc20 knockdown again prevented slippage, and killed all cells
that entered mitosis (red and green lines in Figure 2E), though
this took 2.5-fold longer in time on average than normal HeLa
(compare red and green lines in Figures 2A and 2E).
These data allow several conclusions. First, Cdc20 knock-
down efficiently promotes death during mitotic arrest. In lines
that tend to die inside mitosis in kinesin-5 inhibitor, Cdc20
knockdown is equally effective at promoting death, but in lines
that tend to slip before they die, it is much more effective.
Second, because Cdc20 knockdown blocks slippage, these
data allow us to compare the rate of death induction during
mitotic arrest among the lines, without the complication of slip-
page. The median times for induction of death in Cdc20 knock-
down were: HeLa 18.0 hr, MDA-MB-435S 24.3 hr, MCF7 39.8 hr,
A549 40.0 hr, HeLa overexpressing Bcl2 40.8 hr. Thus, death
induction rates during mitotic arrest were 2.5-fold faster in
the most death-sensitive line compared with the most resistant.
This relatively small difference in death induction rate translates
into a much larger difference in survival in kinesin-5 inhibitor
(0% in HeLa compared with >70% in MCF7, A549 and HeLa
overexpressing Bcl2) because slippage intervenes to rescue
the slower-dying lines, as proposed in the competing pathway
model (Gascoigne and Taylor, 2008). Finally, in HeLa cells Bcl2
overexpression confers strong resistance to kinesin-5 inhibitor,
but not to Cdc20 knockdown.
We next extended the comparison to paclitaxel, a drug with
proven activity in solid tumors (Jordan and Wilson, 2004). Again,
we used a drug concentration that was saturating for mitotic
arrest and failure of cytokinesis in all lines, to avoid complications
from drug efflux pump or tubulin isotype differences. Across the
panel, addition of Cdc20 knockdown to paclitaxel was always
as, or more, efficient than paclitaxel alone at inducing cell death
(Figures 2F–2J). In some lines, paclitaxel is more proapoptotic
than kinesin-5 inhibitor. The duration of mitotic arrest was essen-350 Cancer Cell 16, 347–358, October 6, 2009 ª2009 Elsevier Inc.tially the same for both drugs in all lines, and the extra cell death
in paclitaxel manifested mostly after slippage (Table 1; Shi et al.,
2008). In the more death-sensitive lines (HeLa, MDA-MB-435S),
paclitaxel and kinesin-5 inhibitor caused death with similar
kinetics, and Cdc20 knockdown killed with either the same
(HeLa) or somewhat greater (MDA-MB-435S) efficiency. Death-
resistant MCF7 cells responded similarly to the two drugs, and in
this line Cdc20 knockdown killed with much greater efficiency
than either drug. A549 cells were killed more efficiently by pacli-
taxel than kinesin-5 inhibitor, but Cdc20 knockdown was yet
more efficient. HeLa overexpressing Bcl2 was intermediate
between MCF7 and A549. Overall, although paclitaxel was
somewhat more efficient at promoting killing than kinesin-5
inhibitor in some apoptosis-resistant lines, Cdc20 knockdown
was always more efficient than either drug.
A priori, we do not expect Cdc20 knockdown to perturb
spindle assembly or activate the SAC. To test whether Cdc20
knockdown perturbs spindle assembly, we imagedmicrotubules
live in HeLa stably expressing green fluorescent protein (GFP)
b-tubulin (Figure 3). We observed normal bipolar spindles early
in the arrest, which gradually became multipolar and abnormal
over hours. From these images, it seems likely that the SAC is
not activated early in the Cdc20 knockdown arrest, though it
may be activated later. Because combining Cdc20 knockdown
and kinesin-5 inhibitor showed similar death kinetics to Cdc20
knockdown alone in all lines (red and green lines in Figures 2A–
2E), we used this combination in most subsequent experiments.
By deliberately activating the SAC, we removed the ambiguity of
whether it was activated. Combination with drugs was also more
reliable for blocking slippage than Cdc20 knockdown alone in
cell lines where transfection efficiency was variable.
Cdc20 Knockdown Slows Cyclin B1 Proteolysis
To determine how Cdc20 knockdown prevents slippage, we
imaged cells infected with adenovirus expressing full-length
cyclin B1 fused to enhanced green fluorescent protein (EGFP)
(Bentley et al., 2007). We first confirmed that our cyclin B1-EGFP
expression did not affect normal mitosis, duration of drug-
induced mitotic arrest, or kinetics of cell death (data not shown).
In HeLa, where most cells died in mitosis in kinesin-5 inhibitor,
cyclin B1 levels gradually decreased to 30%–60% of the starting
value by the time of death (Figure 4A, n > 30). In A549, where
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Figure 3. Knockdown of Cdc20 Induces Spindle Damage over Time
Time evolution of mitotic spindles from two representative HeLa-GFP-b-tubulin cells. Cells were transfected with Cdc20 siRNA and monitored by time-lapse
microscopy. Numbers indicate elapsed time (hour: minute) relative to mitotic entry. The scale bar represents 5 mm.most cells slipped out of arrest without dying in kinesin-5 inhib-
itor, cyclin B1 levels slowly decreased, until they were 0%–10%
of the level at the start of mitosis, when the cell slipped by
morphological criteria (Figure 4B, n > 40). We observed consid-
erable cell-to-cell variation in the shape and slope of cyclin B1
decrease kinetics, as wemight expect because slippage kinetics
are highly variable from cell to cell (Gascoigne and Taylor, 2008;
Orth et al., 2008), but slippage always correlated with the time
that cyclin B1 levels were reduced to 0%–10% of their starting
value. When Cdc20 was depleted, cyclin B1 levels declined
more slowly, especially in A549 (Figures 4B and 4D). In this situ-
ation, each time course ended when the cell underwent death in
mitosis, which occurred on average 18.8 ± 7.3 hr (n = 98) after
mitotic entry in HeLa, and 43.8 ± 16.5 hr (n = 101) in A549. At
this time, cyclin B1 levels were 50%–90% of their mitotic entry
value in HeLa, and 30%–70% in A549. Similar results were foundwhen we used HeLa and A549 lines stably expressing full-length
cyclin-B1-EYFP, suggesting that such degradation kinetics is
not specific to adenovirus-mediated expression of cyclin-B1-
EGFP (see Figure S1 available online). We conclude that Cdc20
knockdown stabilizes cyclin B1 levels during mitotic arrest more
efficiently than SAC activation via kinesin-5 inhibition. This pre-
sumably explains why arrest is sustained for longer in Cdc20
knockdown, which gives cells more time to die in mitosis. These
data are also consistent with a previous hypothesis that slippage
is due to slow proteolysis of cyclin B1 by leaky activity of the
APC/CCdc20 - proteasome pathway even when SAC is active
(Brito and Rieder, 2006), though a potential complication is the
recent observation that cyclin B1 turns over with a half life of
1–2 hr, so its gradual loss presumably reflects a balance
between synthesis and proteolysis (Nilsson et al., 2008). Other
mitotic cyclins could potentially contribute to Cdc20Cancer Cell 16, 347–358, October 6, 2009 ª2009 Elsevier Inc. 351
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Mitotic Exit as an Antimitotic Targetknockdown-mediated mitotic arrest, because depletion of
Cdc20 also stabilizes other APC/CCdc20 substrates, for example
cyclin A (Sigrist et al., 1995; Wolthuis et al., 2008).
Death Induced by Cdc20 Knockdown Does Not Depend
on SAC Activity
Loss or weakening of SAC activity confers strong resistance
to SAC-dependent antimitotic drugs in various cancer cell lines
(Taylor and McKeon, 1997; Shin et al., 2003; Tao et al., 2005;
Swanton et al., 2007; Gascoigne and Taylor, 2008; Bekier
et al., 2009). To test whether Cdc20 knockdown can efficiently
kill SAC-deficient cells, we knocked down individual SAC
proteins in HeLa cells by siRNA transfection, testing Mad2,
BubR1, Mps1, and Bub3 (Figure 5A). Mad2, BubR1, and Bub3
are present in the mitotic checkpoint complex (MCC) that
sequesters Cdc20, and Mps1 is an essential kinase in the SAC
pathway (Musacchio and Hardwick, 2002; Musacchio and
Salmon, 2007). Each knockdown drastically decreased the
duration of mitotic arrest in kinesin-5 inhibitor, confirming that
SAC activity was removed (Figure 5B). Next, we co-knocked
down Cdc20 with individual SAC proteins. To avoid competition
between siRNA duplexes, HeLa cells were first transfected with
Mad2, BubR1, Mps1, or Bub3 siRNA, followed by a second
transfection 6 hr later with Cdc20 siRNA. Immunoblots con-
firmed the efficiency of co-knockdown (Figure 5A). The robust
mitotic arrest induced by Cdc20 knockdown was unaffected
by co-knockdown of any of the SAC proteins (Figure 5B), con-
firming that the arrest was SAC independent, as expected
from a linear topology of the mitotic arrest pathway (Figure 1A).
We then compared the effects of SAC protein knockdown on
death induced by kinesin-5 inhibitor with that induced by
Cdc20 co-knockdown. Death induced by kinesin-5 inhibitor in
HeLa cells was greatly attenuated by knockdown of SAC
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Figure 4. Knockdown of Cdc20 Slows
Cyclin B1 Proteolysis
Changes of cyclin B1 level over time from five
representative HeLa or A549 cells treated with
kinesin-5 inhibitor or Cdc20 siRNA. Cells infected
with adenovirus expressing full-length cyclin
B1-GFP were treated as indicated and monitored
by time-lapse microscopy. Fluorescent intensity
(with subtraction of background) was normalized
by the highest intensity in the time course for
each cell. T = 0 marks mitotic entry.
(A) HeLa cells died inmitosis under kinesin-5 inhib-
itor.
(B) A549 cells slipped out of mitotic arrest induced
by kinesin-5 inhibitor.
(C) HeLa cells died in mitosis when treated with
Cdc20 siRNA.
(D) A549 cells died in mitosis when treated with
Cdc20 siRNA.
proteins (Figure 5C), consistent with the
view that SAC activity is required for cell
killing by conventional spindle-perturbing
drugs. Death induced by Cdc20 co-
knockdown, in contrast, was unaffected
by knockdown of any of the four SAC
proteins investigated (Figure 5C). To test whether this result is
cell-type dependent, we knocked down Mad2 in the other three
lines (Figure 5D). Although mitotic arrest and cell death induced
by kinesin-5 inhibitor were sensitive to ablation of Mad2 in all
cases, those induced by co-knockdown of Cdc20 were not
(Figures 5E and 5F). In each case, death kinetics during mitotic
arrest in the absence of Mad2 (Figure 5E) were similar to those
in its presence (Figure 2). Similar results were obtained when
paclitaxel was used as the antimitotic drug (Figures S2A–S2D).
We conclude Cdc20 knockdown is equally effective at killing
SAC-competent and SAC-deficient cancer cells, or phrased
differently, death induced by knockdown of Cdc20 are SAC
independent.
Cdc20 Knockdown Induces Death by MOMP
and Non-MOMP Pathways
Antimitotic drugs that work through SAC activation are thought
to trigger cell death mainly via the intrinsic, or mitochondrial
apoptosis pathway, where the committed step is mitchondrial
outer membrane permeabilization (MOMP) (Wang et al., 1999;
Park et al., 2004; Tao et al., 2005; Bergstralh and Ting, 2006;
Letai, 2008). To confirm this, and to score activation of this
pathway in live cells, we generated stable cell lines expressing
a previously validated live-cell reporter for MOMP, IMS-RP
(Albeck et al., 2008). IMS-RP was created by fusing RFP to the
mitochondrial import sequence of Smac (residues 1–59) (Albeck
et al., 2008). MOMP during mitotic arrest was evident in
HeLa-IMS-RP cells treated with kinesin-5 inhibitor. After many
hours of arrest, IMS-RP relocalized abruptly from a punctate,
mitochondrial distribution to a smooth, cytosolic distribution.
Ten to thirty minutes later (our accuracy was limited by the
time-lapse interval), cells initiated vigorous blebbing, followed
by complete cessation ofmovement that we scored as cell death352 Cancer Cell 16, 347–358, October 6, 2009 ª2009 Elsevier Inc.
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was overexpressed in death-sensitive HeLa-IMS-RP cells,
MOMP was prevented as expected. In cells arrested in kine-
sin-5 inhibitor, IMS-RP remained its punctate mitochondrial
distribution, and cells eventually slipped out of arrest with mito-
chondria intact, and survived until the end of the experiment
(Figure S3B, n > 30). These observations confirm that death
during mitotic arrest induced by kinesin-5 inhibitor in HeLa
occurs by the intrinsic, MOMP-dependent apoptotic pathway.
MOMP also did not occur during mitotic arrest in naturally
death-resistant A549-IMS-RP cells. Most of these cells slipped,
survived, and went on to attempt another round of division with
mitochondria intact (Figure S3C, n > 50).
We used the MOMP reporter to address whether Cdc20
knockdown also causes cell death by intrinsic apoptosis. In
HeLa-IMS-RP cells knocked down for Cdc20, MOMP during
mitotic arrest was unambiguously scored by eye 10–30 min prior
to morphological cell death (Figure 6A, n > 50). As an unbiased
check on this visual observation, we measured standard devia-
tion of the pixel intensity of the MOMP reporter, and found that
it dropped sharply prior to death, as the probe dispersed through
the cytoplasm (Figure 6B). In A549-IMS-RP cells knocked down
of Cdc20, MOMP was also triggered after extended mitotic
arrests (Figure S3D, n > 40).
HeLa cells overexpressing Bcl2 were also efficiently killed by
Cdc20 knockdown (Figure 2E). Because MOMP is strongly in-
hibited in these cells, we wondered if this death, which occurred
2.5 fold more slowly than in wild-type HeLa, was still correlated
with MOMP. By eye, we observed many cases where the
reporter appeared to remain punctate as a cell died during
mitotic arrest. To quantify this, we defined MOMP-uncorrelated
death by failure to detect a sharp decrease in standard deviation
of whole-cell IMS-RP pixel intensity 0–1 hr before initiation of
gross morphological change leading to death in the phase-
contrast channel. More than 80% HeLa overexpressing Bcl2
underwent MOMP-uncorrelated death by this criterion (Figures
6C and 6D, n > 40). The remaining 20%were eitherMOMP corre-
lated or ambiguous.
Combining these data, when MOMP was allowed, all death
events caused by prolonged mitotic arrest, including the unusu-
ally long arrest required to kill resistant A549 cells in Cdc20
knockdown, were MOMP correlated. WhenMOMPwas blocked
by overexpressing Bcl2 in HeLa, cells died anyway, 2.5-fold
more slowly, but now the death was MOMP uncorrelated and
presumably occurred by a different pathway from intrinsic
apoptosis.
An Alternative Method for Blocking Mitotic Exit Has
Effects Similar to Cdc20 Knockdown
To test whether efficient, SAC-independent induction of death
during mitotic arrest was specific for Cdc20 knockdown, or
a general consequence of blocking mitotic exit, we expressed
human cyclin B1 lacking its destruction box (residues 108–
433), fused to EGFP at its C terminus (CT-cyclin-B1-EGFP)
(Bentley et al., 2007). This mutant form of cyclin B1 is resistant
to APC/C-mediated ubiquitination, and known to cause robust
mitotic arrest (Wolf et al., 2006). Immunoblotting confirmed
expression of degradation-resistant cyclin B1 and increased
level of endogenous cyclin B1 in HeLa cells (Figure S4A). Expres-sion of this mutant cyclin B1 caused efficient mitotic blockade,
and efficient cell killing, which was unaffected by RNAi knock-
down of SAC proteins (Figures S4B and S4C). We conclude
that the precise mechanism by which mitotic exit is blocked is
not important for efficient killing of cancer cells.
DISCUSSION
Blocking Mitotic Exit versus Perturbing Spindle
Assembly as Cancer Cell Killing Mechanisms
All approved antimitotic drugs, which target microtubule
dynamics, and most experimental, spindle-specific drugs,
work at least in part by activating the SAC (Jackson et al.,
2007). Possible exceptions are Aurora B kinase inhibitors, which
inhibit aspects of the SAC as well as damaging the spindle (Hauf
et al., 2003). Several authors have hypothesized that reduced
SAC activity in some cancer cells, or increased slippage rate,
may reduce sensitivity to killing by spindle-perturbing drugs
(Taylor and McKeon, 1997; Shin et al., 2003; Tao et al., 2005;
Swanton et al., 2007; Gascoigne and Taylor, 2008; Bekier
et al., 2009). Our data support this view, and further show that
blocking cells in mitosis by a SAC-independent, slippage-resis-
tant mechanism can trigger death more effectively that a SAC-
dependent drug. In death-resistant lines, Cdc20 knockdown
was much more effective than kinesin-5 inhibition for promoting
cell death, whereas in death-sensitive lines the two treatments
were similar. Two effects appear to account for this difference:
death was induced during mitotic arrest 2-fold faster in sensi-
tive than resistant lines, and slippage occurred slightly more
slowly in sensitive lines. Because induction of death and
slippage occur over similar time scales, and they appear to
compete to determine cell fate (as proposed by Gascoigne
and Taylor, 2008), the net effect is a large difference in total
death in response to kinesin-5 inhibitor, but only a 2-fold slow-
ing of death, with all cells eventually dying, in Cdc20 knock-
down. We do not know how common the phenotypes of fast
slippage and/or slow apoptosis are in actual human tumors,
but the fact that we observed them in two of the four solid tumor
derived lines tested suggests they may be common. Perhaps
this is one reason why spindle-specific drugs have shown
only marginal efficacy against solid tumors (Jackson et al.,
2007).
The clinically proven drug paclitaxel causes additional post-
slippage death compared with the kinesin-5 inhibitor we used
in some cell lines, especially in A549 cells, despite promoting
the same duration of mitotic arrest (Figure 2 and Table 1; Shi
et al., 2008). We do not have a clear molecular explanation to
account for this difference in death response; based onmorpho-
logical clues, we speculate it might come from micronucleation,
or microtubule stabilization after cells slip. Although execution of
the death pathway is postslippage, it requires a critical duration
of mitotic arrest; when we deliberately shortened the duration of
arrest by knocking downMad2 in A549 cells, postslippage death
in paclitaxel was strongly inhibited (Figure 2I and Figures S2C
and S2D). Although paclitaxel is better at promoting postslip-
page death in some lines, blocking mitotic exit downstream of
the SAC was overall far more effective than either drug at
promoting death of cells that enter mitosis.Cancer Cell 16, 347–358, October 6, 2009 ª2009 Elsevier Inc. 353
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Figure 5. SAC-Independent Mitotic Arrest and Subsequent Death by Knockdown of Cdc20
(A) Knockdown of various SAC proteins and co-knockdown with Cdc20. HeLa cells were transfected with various siRNA duplexes, and cell lysates were immu-
noblotted as indicated.
(B) Knockdown of SAC proteins abrogates kinesin-5 inhibitor-induced arrest, but has no effect on arrest induced by Cdc20 knockdown. HeLa cells were trans-
fected with indicated SAC protein (or lamin A/C as control) siRNA for 6 hr, followed by a second transfection of Cdc20 siRNA for 6 hr or addition of kinesin-5
inhibitor (with control siRNA). Duration of mitosis was measured by time-lapse microscopy. Numbers in parentheses indicate n. Error bars represent standard
deviation (SD).
(C) Knockdown of SAC proteins attenuates kinesin-5 inhibitor-induced death, but has no effect on death induced by co-Cdc20 knockdown. HeLa cells were
treated as described in (B), and cumulative survival curves were plotted as a function of time since mitotic entry.
(D) Knockdown of Mad2 and coknockdown with Cdc20. MDA-MB-435S, MCF7 and A549 cells were transfected with siRNA duplexes, and cell lysates were
immunoblotted as indicated.
(E) Knockdown of Mad2 abrogates kinesin-5 inhibitor-induced arrest, but has no effect on arrest extended by Cdc20 coknockdown. MDA-MB-435S, MCF7 and
A549 cells were treated and analyzed as described in (B). Instead of Cdc20 siRNA transfection alone, kinesin-5 inhibitor was added 12 hr after transfection to
improve efficiency of mitotic arrest. Numbers in parentheses indicate n. Error bars represent SD.354 Cancer Cell 16, 347–358, October 6, 2009 ª2009 Elsevier Inc.
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(A) Phase-contrast and IMS-RP time-lapse sequence of a representative HeLa cell transfected with Cdc20 siRNA (shown in blue in B). The scale bar represents
5 mm.
(B) Time course of IMS-RP standard deviation from three representative HeLa cells transfected with Cdc20 siRNA.
(C) Phase-contrast and IMS-RP time-lapse sequence of a representative HeLa Bcl2 overexpresser transfected with Cdc20 siRNA (shown in blue in D). The scale
bar represents 5 mm.
(D) Time course of IMS-RP standard deviation from three representative HeLa Bcl2 overexpressers transfected with Cdc20 siRNA.Cdc20 as a Potential Drug Target
Cdc20 was discovered as an essential gene for cell-cycle
progression in budding yeast (Hartwell et al., 1973), and was
recently identified in dropout screens for genes that are required
for human cancer cell proliferation (Schlabach et al., 2008).
Whether Cdc20 is absolutely required for mitotic exit in human
cells is still controversial (Li et al., 2007; Wolthuis et al., 2008;
Baumgarten et al., 2009). In this study, we showed that siRNA
knockdown of Cdc20 causes prolonged mitotic arrest in all lines
tested, and it can be rescued by an RNAi-resistant transgene in
at least one line. This argues against the existence of APC-inde-
pendent mitotic exit pathways (Clarke, 2009).
Is Cdc20 is a ‘‘druggable target’’ in the sense that potent,
specific small-molecule antagonists could be developed? The
most obvious inhibition strategy would be a small molecule
that binds to APC/C and competes at the Cdc20 binding site,
or vice versa. However, this may not be the only option. MCCparticipates in complex interactions with various E3s and
DUBs (enzymes that add and remove ubiquitin) (Reddy et al.,
2007; Stegmeier et al., 2007), and Cdc20 is thought to undergo
fast turnover during mitosis in some cells (Nilsson et al., 2008).
Thus, it might be possible to remove Cdc20 by antagonizing its
translation or deubiquitination. A negative for druggability of
Cdc20 is that it must be almost completely inhibited (<5%
activity remaining [Wolthuis et al., 2008]) to block mitotic exit,
so mitotic arrest by Cdc20 inhibition alone might require a potent
inhibitor. However, Cdc20 inhibitors need not be used alone.
Combined with a conventional antimitotic drug, Cdc20 inhibitors
should suppress slippage, and thus potentiate cell killing.
Other proteins required for mitotic exit could also be consid-
ered as targets. Similar effects of Cdc20 knockdown and degra-
dation-resistant cyclin B1 expression suggest that any blockade
to mitotic exit will have the same lethal effect on cancer cells.
One approach to finding a druggable target in mitotic exit would(F) Knockdown of Mad2 attenuates kinesin-5 inhibitor-induced death, but has no effect on death induced by Cdc20 coknockdown. MDA-MB-435S, MCF7 and
A549 cells were treated and analyzed as described in (C). Mad2 was used as a representative SAC protein, and kinesin-5 inhibitor combined with Cdc20 knock-
down was used instead of Cdc20 knockdown alone to improve efficiency of mitotic arrest.Cancer Cell 16, 347–358, October 6, 2009 ª2009 Elsevier Inc. 355
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has been ablated. SAC ablation would eliminate the large
number of tubulin inhibitors that dominate hits from conventional
cell-based screens for mitotic arrest (Mayer et al., 1999).
Implication for the Death-Triggering Mechanism
during Mitotic Arrest
A major unsolved question for antimitotic drugs is the molecular
mechanism by which spindle damage triggers death during
mitotic arrest. One long-standing question is the SAC’s role in
this process (Taylor and McKeon, 1997; Shin et al., 2003; Tao
et al., 2005; Swanton et al., 2007; Gascoigne and Taylor, 2008;
Bekier et al., 2009). Because mitotic arrest and SAC activation
are normally coupled, simply ablating the SAC and showing
reduced apoptosis in drugs does not distinguish whether the
SAC triggers apoptosis directly, or only indirectly, by promoting
arrest (Weaver and Cleveland, 2005). We uncoupled arrest from
SAC activation, by using Cdc20 knockdown or degradation-
resistant cyclin B1 expression, to promote an SAC-independent
mitotic arrest. We showed that death induction were unaffected
by co-knockdown of any of four SAC proteins investigated under
these conditions (Figure 5C and Figure S4B). This suggests that
some general feature of mitotic arrest, not the SAC activity, is the
proximal trigger for apoptosis.
With respect to identifying the prodeath (and prosurvival)
signal during mitotic arrest, finding that the SAC is not required
for death is somewhat disappointing, because the SAC is a
discrete pathway involving a small number of proteins, whereas
mitotic arrest is a broad change in cell physiology that perturbs
essentially every system in the cell. In death-sensitive HeLa cells,
the kinetics of cell death during mitotic arrest were the same for
Cdc20 knockdown, two different spindle-damaging drugs, and
combinations of either drug with Cdc20 knockdown (Figures
2A and 2F). This suggests that the strength of the signal is unaf-
fected by the state of the mitotic spindle, and is thus unlikely to
emanate from anymicrotubule-based system. This signal seems
to be slowly cumulative because long durations of arrest are
required to trigger death, and to have some memory, because
death that depends on long mitotic arrest can occur several
hours after slippage. In most of the cells we studied, the signal
eventually triggered MOMP, and blocking MOMP by Bcl2 over-
expression slowed death, suggesting the signal impinges on the
Bcl2-family circuitry that regulates MOMP (Letai, 2008). How-
ever, it may act in others ways because Bcl2-overexpressing
cells eventually died in mitotic arrest by a non-MOMP pathway,
similar to other situations where stressed cells die by alternative
programmed death pathways when the canonical apoptosis
pathway is blocked (Degterev and Yuan, 2008). There is a large
literature on the molecular nature of the signal, suggesting the
involvement of Bcl2, Bcl-xL, and caspase-9 phosphorylation,
and various kinase signaling pathways including c-Jun
N-terminal kinase, ERK, p38 MAP kinase, and AKT (Bacus
et al., 2001; Salah-Eldin et al., 2003; Basu and Haldar, 2003;
Deacon et al., 2003; Allan and Clarke, 2007; Mhaidat et al.,
2007; Kim et al., 2007). However, no clear and general picture
has yet emerged, and it remains an area of intensive study. We
speculate that this cumulative, death-inducing signal is gener-
ated by one or more of the general changes in cell physiology
that occur during mitosis, for example in membrane organiza-356 Cancer Cell 16, 347–358, October 6, 2009 ª2009 Elsevier Inc.tion, transcription, translation, metabolism, or signaling. Eluci-
dating this signal will be challenging, but knowing its precise
nature is not required to harness it for killing cancer cells that
enter mitosis, either by SAC activation for current drugs, or by
blocking mitotic exit as we propose.
EXPERIMENTAL PROCEDURES
Cell Lines and Drugs
HeLa, MDA-MB-435S, MCF7, A549, and 293 cells were cultured according to
ATCC recommendations. HeLa GFP-b-tubulin line was a gift from Paul Chang,
and HeLa Bcl2-overexpression line was a gift from Peter Sorger. Reference
spindle-perturbing drugs were used at concentrations that are saturating for
mitotic arrest (Shi et al., 2008; Orth et al., 2008): EMD534085 (European patent
number WO2005063735, provided by Merck Serono) at 1 mM, and paclitaxel
(Sigma) at 200 nM.
siRNA
For Cdc20 depletion, Ambion Silencer Select siRNA against Cdc20 (s2748)
(duplex 1) was used in all experiments at a final concentration of 50 nM; Dhar-
macon ON-TARGETplus siRNA duplex against Cdc20 (J-003225-14) was
used as an alternative (duplex 2) at 100 nM. To deplete SAC proteins, Dharma-
con siGENOME or ON-TARGETplus duplexes against Mad2 (J-003271-13),
BubR1 (D-004101-04), Mps1 (D-004105-03), and Bub3 (D-006826-01) were
used at 40 nM. Dharmacon Lamin A/C siRNA duplex was used as controls.
siRNA transfection was performed using Lipofectamine 2000 (Invitrogen) or
HiPerFect (QIAGEN) according to the manufacturer’s instructions.
Plasmids and Virus Production
Two extra silent mutations were introduced to mouse Cdc20 cDNA (Open
Biosystems) in the area corresponding to human Cdc20 siRNA duplex 1 by
polymerase chain reaction (PCR) mutagenesis. The PCR oligos used are: 50-
CGAAATCCGGAATGACTACTATTTGAATCTTGTAGATTGGAGC-30 and50-GC
TCCAATCTACAAGATTCAAATAGTAGTCATTCCGGATTTC-30. Mouse Cdc20
mutant was subcloned into pBabe-puro retroviral expression vector. Retroviral
IMS-RP and full-length cyclin-B1-EYFP construct were gifts from Peter Sorger
and Jagesh Shah, respectively. Retrovirus was produced in 293 cells and used
to infect HeLa or A549 cells to create stable lines as described previously
(Zheng and Cantley, 2007). Adenoviruses expressing vector-EGFP, full-length
cyclin-B1-EGFP, and CT-cyclin-B1-EGFP were gifts from Randy King and
amplified in 293 cells as described elsewhere (Hoyt and King, 2005).
Immunoblot Analysis
Cell lysates in LDS sample buffer (NuPAGE, Invitrogen) were resolved on 12%
Tris-HEPES gels (Pierce) and transferred to nitrocellulose membranes. Immu-
noblotting was performed according to the manufacturers’ recommendations
with enhanced chemiluminescence (Amersham). Antibodies against Cdc20
and Bub3 were purchased from Abcam; Mad2, BubR1, tubulin, and actin
from Sigma; Mps1 from Upstate; cyclin B1 from Lab Vision.
Time-Lapse Imaging
Cells were seeded in glass-bottom plates (MatTek) in CO2-independent
medium (Invitrogen) supplemented with 10% fetal bovine serum, 100 U/ml
penicillin, and 100 mg/ml streptomycin. For fluorescent time-lapse imaging
cells were seeded in phenol red-free CO2-independent medium (Invitrogen).
Image acquisition was performed using Nikon TE2000 automated inverted
microscope with a 20 3 objective enclosed in a humidified incubation
chamber maintained at 37C. Images were collected every 10–30 min with a
motorized stage. Images were viewed and analyzed with MetaMorph software
(Molecular Dynamics).
SUPPLEMENTAL DATA
Supplemental Data include four figures and can be foundwith this article online
at http://www.cell.com/cancer-cell/supplemental/S1535-6108(09)00293-1.
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